Author

Steffen Johannes Keller

University of FreiburgORCID 0009-0004-8360-0999Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Genetics· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1 Research Focus:metabolism & bioenergetics· 1

Frequent Co-Authors

Asma Y. AlrawashdehiD· 2 shared Dietrich Alexander RuessiD· 2 shared Dominik von ElverfeldtiD· 2 shared Geoffroy AndrieuxiD· 2 shared Huda Jumaa· 2 shared Melanie BoerriesiD· 2 shared Philipp HafneriD· 2 shared Solène BessoniD· 2 shared

Activity by Year

2020-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Asma Y. AlrawashdehORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

ImmunologybioRxivPreprintMay 27, 2026

Immunomodulatory impact of PTPN11/SHP2-based vertical RAS-MAPK pathway inhibition in pancreatic cancer

Asma Y. Alrawashdeh, Xun Chen, Philipp Hafner…·Dietrich Alexander Ruess

This study investigates the immunomodulatory effects of SHP2-based vertical RAS pathway inhibition in pancreatic cancer, revealing both immune-activating and suppressive changes that evolve with treatment.

DOI 10.64898/2026.05.23.727401

humanmouse

𝕏 PostBluesky

Cancer BiologySignal Transduction and Targeted TherapyPeer-reviewedJan 16, 2026

Vertical RAS-pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations

Philipp Hafner, Steffen Johannes Keller, Xun Chen…·Dietrich Alexander Ruess

This study shows that dual SHP2/MEK inhibition in pancreatic cancer causes mitochondrial changes and ROS elevation, leading to a therapy-resistant state that can be targeted with GPX4 inhibition.

9 citationstop 1%

humanbulk RNA-seq

𝕏 PostBluesky

GeneticsHuman Molecular GeneticsPeer-reviewedAug 18, 2020

Abundance and localization of human UBE3A protein isoforms

Carissa L. Sirois, Judy E. Bloom, James J. Fink…·Stormy J. Chamberlain

The paper investigates the abundance and localization of human UBE3A protein isoforms and their impact on Angelman Syndrome phenotypes using CRISPR/Cas9-generated isogenic cells.

34 citations

humanproteomics

𝕏 PostBluesky